CD274 and colitis: In the combined PD-L1 ≥ 1% and < 1% population, the most common (≥ 10%) any-grade IMAEs with nivolumab plus ipilimumab were rash (47%), diarrhea/colitis (18%), adrenal insufficiency, hypothyroidism/thyroiditis, and hypophysitis (12% each), and hyperthyroidism and pneumonitis (11% each); the most common (≥ 5%) grade 3–4 IMAEs were hypophysitis (8%), adrenal insufficiency, diabetes mellitus, and rash (6% each), and diarrhea/colitis, pneumonitis, and hepatitis (5% each) (Table 6).